期刊文献+

老年骨质疏松性椎体压缩性骨折患者术后应用唑来膦酸的预见性护理 被引量:6

Predictive nursing of zoledronic acid in postoperative patients with Senile osteoporotic Vertebral compression fractures
下载PDF
导出
摘要 目的探讨老年骨质疏松性椎体压缩性骨折术后使用唑来膦酸患者的预见性护理。方法对2014年8月~2015年12月172例符合条件的骨质疏松性椎体压缩性骨折术后采用静脉注射唑来膦酸治疗的患者为研究对象,利用随机数字表法进行分组,分别设为实验组和对照组,每组86例。对照组给予常规护理,实验组则实施预见性护理,比较两组患者的药物不良反应、再次用药依从性、护理满意度。结果实验组患者的药物不良反应明显低于对照组(P<0.05),再次用药依从性、护理满意度明显高于对照组(P<0.05)。结论实施预见性护理措施可减轻患者疼痛、减少药物不良反应,提高再次用药依从性和患者满意度,有效预防再骨折的发生。 obiective To investgate the prospective nursing care of patients with zoledronic acid after osteoporotic vertebral compressionfractures. Method A total of 172 eligible patients with osteoporotic vertebral compression fractures were treated with intravenous zoledronic acid from Aug 2014 to Dec 2015. The patients were divided into groups by random number table method. The experimental group and the control group,86 cases in each group,the Control group were given routine care,the experimental gronp in the implementation nf preditive care. Then compare the two groups of Patients with adverse drug reactions, medication compliance,care satisfaction. Results Adverse drug reactions in the experimental group were significantly lower than those in the control group,and compliance with medication and nursing satisfaction were signifificantly higher than those in the control group. Conclusion The implementation of preditive care ean reduce the pain and adverse drug reactions,improve complisance and satisfaction,and prevent the occurrence of fractures effective.
出处 《当代护士(上旬刊)》 2017年第2期4-5,共2页 Modern Nurse
基金 卫生部医药卫生科技发展研究中心课题,项目编号:w2012zT l4
关键词 唑来膦酸 骨质疏松 脊柱骨折 预见性护理 Zoledronic Acid Osteoporosis Spinal Fractures Predictive Nursing
  • 相关文献

参考文献6

二级参考文献31

  • 1潘运霞,文芝清.冠心病介入治疗术后腹胀不适的相关因素探讨[J].当代护士(中旬刊),2005,12(4):26-27. 被引量:9
  • 2吕靖,马彩玲.绝经后骨质疏松症的治疗新进展[J].医学综述,2007,13(1):62-63. 被引量:37
  • 3王辰.肺栓塞.北京:人民卫生出版社,2004:185—194.
  • 4Siris ES, Harris ST, Rosen CJ, et al. 2006 Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases [ J]. Mayo Clin Proc. 2006, 81 ( 8 ) : 1013- 1022.
  • 5Nancollas GH, Tang R, Phipps R J, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite[ J ]. Bone, 2006, 38 (5) :617-627.
  • 6Aclasta Basic Prescribing Information. Novartis Pharma AG.
  • 7Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronie acid for treatment of postmenopausal osteoporesis [ J]. N Engl J Med, 2007, 356 ( 18 ) : 1809-1822.
  • 8Lyles KW, Col6n-Emerie CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture[ J]. N Engl J Med, 2007, 357(18) :1799-1809.
  • 9Masarachia P, Weinreb M, Balena R, et al. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones[J]. Bone, 1996, 19(3) :281-90.
  • 10Coxon FP, Thompson K, Roelofs AJ, et al. Visualizing mineral binding and uptake of bisphosphonate by osteoelasts and non- resorbing cells[ J ]. Bone, 2008, 42 (5) : 848-60.

共引文献76

同被引文献50

引证文献6

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部